Related Experiment Video
Updated: May 30, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Respiratory syncytial virus infection in adults
1Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14621, USA. edward.walsh@rochestergeneral.org
Insights
Respiratory syncytial virus (RSV) causes significant illness in infants and adults. Current treatments are limited, highlighting the urgent need for an effective RSV vaccine.
Area of Science:
- Virology
- Infectious Diseases
- Public Health
Background:
- Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in infants, leading to significant hospitalizations and deaths.
- RSV also causes substantial disease in adult populations, including the elderly, immunocompromised, and those with chronic conditions, though diagnosis is challenging due to low viral shedding.
Purpose of the Study:
- To review the impact of RSV in both pediatric and adult populations.
- To discuss the limitations of current diagnostic methods and antiviral therapies for RSV.
- To highlight the potential of immunization as the most promising strategy for reducing RSV burden.
Main Methods:
- Literature review of RSV epidemiology, clinical manifestations, diagnosis, and treatment.
- Analysis of current therapeutic and prophylactic options, including their limitations in adults.
- Evaluation of immunization strategies for RSV prevention.
Main Results:
- RSV is a leading cause of pediatric respiratory illness but also affects all adult age groups, causing significant morbidity and mortality.
- Molecular tests are optimal for diagnosing RSV in adults, but antiviral therapies like ribavirin and palivizumab have limited efficacy and are primarily used in infants.
- Currently, no effective RSV vaccine is available, representing a critical unmet medical need.
Conclusions:
- RSV poses a significant health threat across all age groups, necessitating improved diagnostic and therapeutic approaches.
- Effective immunization strategies hold the greatest promise for controlling RSV infections and reducing disease burden in the adult population.
- Further research and development are crucial for creating an effective RSV vaccine and improving management of RSV infections.
Abstract:
Respiratory syncytial virus (RSV), an enveloped RNA virus in the Paramyxovirus family, is the most important cause of lower respiratory tract infection in infants and young children, accounting for ~100,000 pediatric hospitalizations and 250 deaths annually in the United States. Despite primarily being recognized as a pediatric pathogen, RSV reinfection causes substantial disease in all adult populations, including healthy young persons, old and frail individuals, those with chronic obstructive pulmonary disease and immunocompromised patients. Most illnesses are mild in adults, but significant morbidity and mortality can develop. In contrast to infants, diagnosis of RSV infections is difficult due to low virus shedding, and optimal diagnosis requires molecular tests. Unfortunately, antiviral therapy is of limited benefit. Ribavirin and palivizumab are the only approved pharmacological agents for RSV treatment and prophylaxis, respectively, and are primarily used in infants; data regarding their usefulness in adults are limited. Currently, specific antiviral therapy is generally reserved for severely immunocompromised patients or severe respiratory failure. The greatest promise for reducing the impact of RSV in adults may be through immunization. However, an effective vaccine for RSV is not currently available.
Related Concept Videos
Respiratory Syncytial Virus Disease
Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Coronavirus
Pulmonary Cycle: Exhalation
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

